ArticlePeerJ2024
Dosimetric comparison and evaluation of different convergence modes in nasopharyngeal carcinoma using VMAT treatment deliveries.
Article in PeerJ, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Beam geometry optimization and convergence mode evaluation for knowledge-based planning of hippocampal avoidance whole-brain radiotherapy: A cross-platform study with quantitative scorecard assessment.Journal of applied clinical medical physics · 2026Article
- Dosimetric impact of aperture-restricted VMAT on heart dose in breast cancer treated with regional nodal irradiation.Journal of applied clinical medical physics · 2026Article
- Volumetric Modulated Arc Therapy Versus Dynamic Conformal Arc Therapy for Single Isocenter Stereotactic Radiotherapy of Multiple Brain Metastases.Bioengineering (Basel, Switzerland) · 2026Article
- Article
- Integrating static angle ports and dynamic collimator rotation in volumetric modulated arc therapy for hypofractionated whole breast irradiation in Chinese females: a single-centre dosimetric study.Radiation oncology (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study investigates the impact of convergence mode (CM) in Eclipse (Varian Medical Systems) on the quality and complexity of volumetric modulated arc therapy (VMAT) plans for nasopharyngeal carcinoma (NPC) patients. Methods: We retrospectively analyzed data from 21 NPC patients. For each patient, three VMAT plans with different CM settings (Off, On, and Extended) were created using identical optimization objectives. Plan quality was assessed using indices such as the conformity index (CI) and homogeneity index (HI), as well as evaluating target coverage and sparing of organs at risk (OARs). Complexity was measured by metrics including average leaf pair opening (ALPO), modulation complexity scores for VMAT (MCSv), monitor units (MUs), and optimization time. Dosimetric verification was performed based on the gamma pass rate. Results: Different CM settings can generate treatment plans that meet clinical dose objectives for planning target volumes (PTVs) and OARs. The 'On' or 'Extended' CM settings improved CI and HI for the NPC target volume and reduced OAR doses, especially the mean dose, without compromising target coverage. The 'Extended' CM setting produced the most favorable outcomes. ALPO values for CM settings 'Off', 'On', and 'Extended' were 29.1 ± 4.3 mm, 28.6 ± 4.2 mm, and 28.4 ± 4. 2 mm, respectively. MCSv values for these settings were 0.1730 ± 0.0215, 0.1691 ± 0.0204, and 0.1693 ± 0.0208, respectively. MUs were 796.2 ± 110.8 for CM 'Off', 798.6 ± 106.1 for CM 'On', and 799.7 ± 103.6 for CM 'Extended', with no significant differences ( Conclusion: CM usage can improve the CI and HI of the target volume and decrease the dose to OARs in VMAT plans for NPC patients. This study suggests that CM can be a valuable tool in VMAT planning for nasopharyngeal carcinoma, given adequate planning time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.